Sign in
Taking people in United StatesPhase 1

BHV-1300 for adults with Graves' disease, looking at safety and markers

Tests BHV-1300 for safety in adults with Graves' disease.

Key facts

Who runs it
Biohaven Therapeutics Ltd.
Where
Canton, Columbus, Dallas, Greenville, Houston, Memphis, Miami, Shavano Park, and South Gate, United StatesSee the 10 sitesAlso in 1 other country, 8 sites
Trial code
Registry title
Study of BHV-1300 in Graves' Disease
Status
Recruiting
Phase
Phase 1
People taking part
15 people, planned
Started
21 Aug 2025
Expected to end
Sept 2027
Type of study
Interventional
Treatments tested
  • BHV-1300
Record updated
31 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease, an immune condition that makes the thyroid overactive. It tests whether BHV-1300 is safe and how it affects disease markers.

Age
18 Years to 65 Years
Sex
All sexes can join.
Disease stage
Graves' disease confirmed by a blood test.
Earlier treatment
People who have had radioactive iodine treatment or thyroid surgery cannot join.
Biomarker or test result
Graves' disease must be confirmed by a blood test (serologically confirmed).

Main reasons for not taking part

  • Overactive thyroid caused by something other than Graves' disease, such as toxic adenoma or toxic multinodular goiter
  • Thyroid storm (a sudden, severe flare of overactive thyroid) within six weeks of the Baseline visit
  • Past radioactive iodine treatment
  • Past thyroid surgery

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participants must have serologically confirmed Graves' Disease

Who cannot take part

  • History of treatment with radioactive iodine or thyroid surgery
  • History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

Also in 1 other country, 8 sites

  • Canton, OhioHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Columbus, GeorgiaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Dallas, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Greenville, North CarolinaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Houston, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Memphis, TennesseeHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Miami, FloridaHospital not named in the registryContact: Chief Medical OfficerTaking people
  • Shavano Park, TexasHospital not named in the registryContact: Chief Medical OfficerTaking people
  • South Gate, CaliforniaHospital not named in the registryContact: Chief Medical OfficerTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

The group in the trial

  • BHV-1300Treatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
Plain-language title
BHV-1300 for adults with Graves' disease, looking at safety and markersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06980649, who can take part
Record updated
31 July 2026